Spravato Success Rate: Does Esketamine Really Work for Treatment-Resistant Depression?
-
What Does “Success” Mean with Spravato?
Spravato Success Rates in Clinical Trials
Real-World Results Outside Clinical Studies
How Quickly Does Spravato Work?
Does the Benefit Last?
Spravato for Treatment-Resistant Depression
What Influences Treatment Success?
Understanding the Limitations
How Spravato Compares with Other Treatments
Spravato Treatment at Amazing Grace Center
Frequently Asked Questions
Does Spravato Really Work?
If you are considering Spravato (esketamine) for depression that has not improved after trying multiple medications, one of the first questions you are likely to ask is whether it actually works. The answer is yes—for many people—but the success rates you find online can be confusing. Some articles report success rates around 50%, while others suggest numbers closer to 80% or even higher.
The difference comes down to how researchers define success. Clinical trials often measure whether symptoms improve by at least half, while some real-world studies report the percentage of patients who experience meaningful overall improvement after completing treatment. When those differences are taken into account, the research becomes much easier to understand.
Overall, clinical trials show that approximately 50% to 70% of patients experience a significant improvement in depression symptoms when Spravato is combined with an oral antidepressant. About 30% to 50% achieve remission, meaning their symptoms improve enough that they no longer meet the criteria for major depression. Outside of clinical trials, many treatment centers report meaningful improvement in 60% to 80% of patients, particularly among those who complete the recommended treatment schedule.
What Does “Success” Mean with Spravato?
Before comparing percentages, it is important to understand what researchers actually mean when they talk about treatment success.
Depression studies use standardized rating scales to measure symptom severity. Two of the most common are the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Patient Health Questionnaire-9 (PHQ-9). These tools allow researchers to compare symptoms before and after treatment using objective measurements rather than personal impressions alone.
The first outcome researchers measure is response. A response generally means that depression symptoms decrease by at least 50% compared with where they started. Someone who responds to treatment usually feels substantially better but may still experience some lingering symptoms. Across major Spravato studies, roughly half to two-thirds of patients reach this milestone.
The second outcome is remission, which is considered the ideal goal of treatment. Remission means symptoms improve to the point that depression is minimal or no longer clinically significant. Depending on the study, approximately 30% to 50% of patients receiving Spravato achieve remission during the initial treatment phase.
Researchers also follow patients over time to measure relapse, or the return of depression after improvement. This helps determine whether treatment benefits are maintained over months rather than just weeks and explains why maintenance treatment remains an important part of the Spravato treatment plan.
These terms are often confused when success rates are discussed online. A clinic advertising an 80% success rate is usually referring to patients who experienced meaningful improvement—not necessarily those who achieved complete remission. Both statistics are valuable, but they describe different treatment outcomes.
Spravato Success Rates in Clinical Trials
The strongest evidence supporting Spravato comes from the large Phase 3 clinical trials that led to FDA approval for treatment-resistant depression in 2019. These studies enrolled adults whose depression had not improved despite trying multiple antidepressant medications.
In the TRANSFORM studies, participants began a new oral antidepressant and were randomly assigned to receive either Spravato nasal spray or a placebo nasal spray. Researchers then measured changes in depression symptoms over four weeks.
The pivotal TRANSFORM-2 trial produced the most encouraging results. Approximately 69% of patients receiving Spravato achieved a treatment response, compared with about 52% of those receiving an antidepressant with placebo. Patients treated with Spravato also experienced greater overall reductions in depression scores by the end of the study.
TRANSFORM-1 showed a similar trend. Around 53% of patients treated with Spravato responded, compared with approximately 31% in the placebo group. Although this particular study did not reach statistical significance for its primary endpoint, the overall pattern remained consistent with findings across the larger clinical development program.
Taken together, these trials demonstrate that adding Spravato to an oral antidepressant increases the likelihood of meaningful improvement by roughly 15% to 20% compared with antidepressant treatment alone. Considering that every participant had already failed multiple medications, this represents an important clinical benefit for a population with limited treatment options.
Real-World Success Rates: Beyond the Clinical Trials
Clinical trials are conducted under carefully controlled conditions, but real-world treatment often tells a broader story. Studies following patients receiving Spravato in routine psychiatric practice generally report outcomes that are comparable to—and sometimes even stronger than—those seen in clinical trials.
Observational studies and treatment registries have found that approximately 60% to 80% of patients experience meaningful improvement after completing several treatment cycles, with the highest success rates typically reported among patients who continue into the maintenance phase. One widely cited real-world analysis found that nearly 88% of patients were rated as “much improved” or “very much improved” within the first three months, and many maintained those improvements during long-term follow-up.
These findings should be interpreted carefully. Real-world studies often report outcomes among patients who complete treatment rather than everyone who starts, and unlike randomized trials, they do not include a placebo comparison group. Rather than contradicting the clinical trial data, they reinforce the same overall conclusion: most patients who complete a full course of Spravato experience meaningful relief, while a substantial minority achieve remission.
How Quickly Does Spravato Work?
One of Spravato’s greatest advantages is how quickly it can begin working. Traditional antidepressants often require four to six weeks before patients notice meaningful improvement. Spravato can produce symptom relief much sooner, with some patients experiencing improvement within 24 to 48 hours after their first treatment. Clinical studies have also demonstrated measurable differences from placebo within the first day.
That rapid onset is one reason Spravato is also FDA-approved for major depressive disorder with acute suicidal ideation or behavior. During a mental health crisis, waiting several weeks for a traditional antidepressant to become effective may not be appropriate. Spravato offers the potential for faster symptom relief while other treatments continue to work.
It is important to remember, however, that a rapid response does not guarantee lasting improvement. Early progress still needs to be reinforced through the complete treatment schedule, which is why the induction and maintenance phases remain an important part of successful Spravato therapy.
Comparing Treatment Types for Depression
| Feature | Oral Medications | TMS | Intranasal Esketamine (Spravato®) | Electroconvulsive Therapy (ECT) |
|---|---|---|---|---|
| FDA Approved For | Depression | Treatment-Resistant Depression | Treatment-Resistant Depression & Depression with Acute Suicidal Ideation | Severe Depression, Catatonia, Psychotic Depression |
| Typical Time to Improvement | 4–8 weeks | 2–6 weeks | 24–48 hours for some patients | 1–3 weeks |
| Response Rate | 30–60% | 50–60% | 50–70% | 70–90% |
| Remission Rate | 20–40% | 30–40% | 30–50% | 50–70% |
| Insurance Coverage | Usually Covered | Often Covered | Often Covered with Prior Authorization | Usually Covered |
| Requires In-Office Treatment | No | Yes | Yes | Yes |
| Anesthesia Required | No | No | No | Yes |
| Driving Restrictions | None | None | Cannot drive until the next day | Requires escort after treatment |
| Typical Candidates | First-line treatment | Depression not responding to medication | Failed two or more antidepressants | Severe or life-threatening depression |
Note: Response and remission rates are approximate ranges reported across published clinical trials and real-world studies. Individual results vary based on diagnosis, severity of depression, medical history, and adherence to treatment.
Does the Benefit Last? Maintenance and Relapse
A strong response rate means little if symptoms return soon after treatment ends, making long-term effectiveness one of the most important questions. Fortunately, research suggests that the benefits of Spravato can be maintained over time, particularly when patients continue with the recommended maintenance schedule.
The landmark SUSTAIN-1 study found that patients who achieved remission or a stable response and continued Spravato treatment were significantly less likely to relapse than those who were switched to placebo. Long-term studies have also reported sustained remission in many patients through the maintenance phase, with approximately 60% to 70% of initial responders maintaining their improvement while continuing treatment.
The practical takeaway is that Spravato is generally not intended to be a one-time treatment. Instead, most patients begin with twice-weekly treatments during the first month before tapering to weekly and eventually every-other-week maintenance sessions. For many people, continued treatment helps preserve the progress achieved during the initial phase.
Spravato Success for Treatment-Resistant Depression
Spravato is not designed for every person living with depression. In the United States, it is FDA-approved for adults with treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior, and the success rates should be understood within those specific groups.
For treatment-resistant depression, research consistently shows that more than half of patients experience meaningful improvement when Spravato is added to an oral antidepressant. Because these individuals have already tried two or more antidepressants without adequate relief, even response rates of 50% to 60% represent an important advance for a population with limited treatment options.
For patients experiencing major depressive disorder with acute suicidal ideation or behavior, the ASPIRE clinical trials demonstrated that Spravato, when combined with comprehensive standard care, produced rapid reductions in depressive symptoms within the first 24 hours. Although the primary goal in these situations is immediate stabilization rather than long-term remission, the studies further demonstrate Spravato’s ability to provide relief more quickly than traditional antidepressants alone.
What Influences Your Spravato Success Rate?
While published research provides average success rates, individual results vary. Completing the recommended induction schedule, continuing into maintenance treatment when appropriate, taking Spravato alongside an oral antidepressant, participating in psychotherapy, and working closely with your psychiatrist all improve the likelihood of success. Some people notice meaningful improvement within days, while others require several weeks before symptoms begin to improve. Regular symptom tracking and timely treatment adjustments also help maximize the chances of achieving and maintaining remission.
Understanding the Limitations
Spravato is an effective treatment for many people with treatment-resistant depression, but it does not work for everyone. Across clinical studies, approximately 25% to 35% of patients do not experience an adequate response despite completing a full course of treatment, while others may require maintenance dosing to prevent relapse. Because every treatment must be administered in a REMS-certified clinic with at least two hours of monitoring, scheduling and transportation can also be barriers for some patients. Side effects such as dizziness, dissociation, nausea, and temporary sedation lead a small percentage of patients to discontinue treatment before completing the recommended course.
How Spravato Compares to Other Depression Treatments
Spravato is one of several advanced treatments available for depression that has not responded to traditional medications. Oral antidepressants remain the first-line treatment but become less effective after multiple medication failures. Transcranial magnetic stimulation (TMS) offers another noninvasive option with comparable response rates, although symptom improvement usually develops more gradually. Electroconvulsive therapy (ECT) remains the most effective treatment for severe or psychotic depression but requires anesthesia and carries greater treatment burden. The best option depends on your diagnosis, previous treatment history, symptom severity, medical conditions, and personal preferences.
Spravato Treatment at Amazing Grace Center
At Amazing Grace Center in Portsmouth, Ohio, we provide REMS-certified Spravato treatment for adults with treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. Before treatment begins, our team performs a comprehensive psychiatric evaluation, verifies insurance benefits, obtains prior authorization when needed, and carefully monitors your response throughout treatment using measurement-based care. Whether Spravato is the right option depends on your individual history and treatment goals, and our role is to help you make an informed decision based on the best available evidence.
Frequently Asked Questions about Spravato for Depression Treatment
-
Clinical trials show that approximately 50% to 70% of patients with treatment-resistant depression experience a significant improvement in symptoms, while 30% to 50% achieve remission. Real-world treatment centers often report meaningful improvement in 60% to 80% of patients who complete treatment.
-
Some patients notice improvement within 24 to 48 hours of their first treatment, although many experience gradual improvement over several weeks as they complete the induction phase.
-
Most patients begin with twice-weekly treatments for four weeks before tapering to weekly and then every-other-week maintenance treatments. The duration of therapy varies based on symptom improvement and the risk of relapse.
-
Many commercial insurance plans, Medicare, and Ohio Medicaid cover Spravato for eligible patients after prior authorization. Coverage and out-of-pocket costs vary depending on your individual insurance plan.
-
No. Spravato is FDA-approved for adults with treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. A psychiatric evaluation is necessary to determine whether it is an appropriate treatment option.
Key Takeaways
Spravato has become an important treatment option for adults whose depression has not improved with traditional antidepressants. Clinical trials consistently demonstrate meaningful response rates of approximately 50% to 70%, while real-world studies often report improvement in 60% to 80% of patients who complete treatment. Although it is not effective for everyone, Spravato offers faster symptom relief than conventional antidepressants and has helped many people achieve meaningful recovery when other treatments have failed. At Amazing Grace Center, our team provides comprehensive evaluations, insurance support, and evidence-based Spravato treatment to help patients determine whether esketamine is the right next step in their recovery.
Medical Disclaimer
This article is intended for educational purposes only and should not be considered medical advice. Published success rates represent averages across clinical studies and real-world practice and cannot predict an individual patient’s outcome. Always consult a qualified psychiatrist to determine the most appropriate treatment for your specific condition.
